Concord Biotech Ltd. | Mid-cap | Healthcare
₹1,565.40
-1.50%
| Concord Biotech Stock Comparison:
Concord Biotech vs BioconConcord Biotech vs OneSource SpecialtyConcord Biotech vs Blue Jet HealthcareConcord Biotech vs Supriya LifescienceConcord Biotech vs Dishman CarbogenConcord Biotech vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 2.0B
Gross Profit 1.6B 77.89%
Operating Income 436.2M 21.38%
Net Income 440.6M 21.60%
EPS (Diluted) ₹4.21

Balance Sheet Metrics

Total Assets 20.3B
Total Liabilities 2.2B
Shareholders Equity 18.1B
Debt to Equity 0.12

Cash Flow Metrics

Revenue & Profitability Trend

Concord Biotech Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i11.8B10.0B8.3B7.1B6.0B
Cost of Goods Sold i3.2B2.4B2.0B1.8B1.2B
Gross Profit i8.6B7.6B6.3B5.3B4.8B
Gross Margin % i73.1%75.8%76.3%74.9%80.1%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i474.4M442.4M342.0M320.2M204.6M
Other Operating Expenses i1.7B1.7B1.6B1.3B760.1M
Total Operating Expenses i2.2B2.1B1.9B1.6B964.7M
Operating Income i4.6B3.9B3.0B2.4B3.0B
Operating Margin % i39.3%38.7%36.7%33.3%50.2%
Non-Operating Items
Interest Income i17.1M30.4M44.4M47.9M17.9M
Interest Expense i5.3M25.5M45.1M54.8M6.7M
Other Non-Operating Income-----
Pre-tax Income i4.9B4.1B3.2B2.4B3.1B
Income Tax i1.2B1.0B819.3M625.9M778.3M
Effective Tax Rate % i24.9%25.3%25.4%26.4%24.9%
Net Income i3.7B3.1B2.4B1.7B2.3B
Net Margin % i31.5%30.9%28.9%24.7%38.9%
Key Metrics
EBITDA i5.3B4.5B3.8B2.9B3.3B
EPS (Basic) i₹35.52₹29.45₹22.95₹16.72₹22.45
EPS (Diluted) i₹35.52₹29.45₹22.95₹16.72₹22.45
Basic Shares Outstanding i104616204104616204104616204104616204104616204
Diluted Shares Outstanding i104616204104616204104616204104616204104616204

Income Statement Trend

Concord Biotech Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i9.0M151.4M35.0M6.7M51.4M
Short-term Investments i3.2B2.7B1.8B1.6B2.0B
Accounts Receivable i5.2B3.5B2.7B2.3B1.8B
Inventory i2.4B2.1B2.1B2.0B1.5B
Other Current Assets153.6M284.9M7.1M--
Total Current Assets i11.4B9.0B7.3B6.3B6.1B
Non-Current Assets
Property, Plant & Equipment i667.9M519.9M493.8M432.2M411.3M
Goodwill i11.2M3.2M2.0M35.8M64.2M
Intangible Assets i11.2M3.2M2.0M35.8M64.2M
Long-term Investments-----
Other Non-Current Assets126.0M79.8M---
Total Non-Current Assets i9.0B8.0B7.9B6.8B5.8B
Total Assets i20.3B17.0B15.1B13.1B11.8B
Liabilities
Current Liabilities
Accounts Payable i1.4B944.4M938.0M831.1M464.0M
Short-term Debt i23.4M78.5M251.5M309.3M314.0M
Current Portion of Long-term Debt-----
Other Current Liabilities113.2M62.7M---
Total Current Liabilities i1.8B1.4B1.9B1.6B1.1B
Non-Current Liabilities
Long-term Debt i6.3M18.9M64.0M315.6M578.8M
Deferred Tax Liabilities i340.2M280.6M234.4M209.7M174.5M
Other Non-Current Liabilities-----
Total Non-Current Liabilities i374.7M319.1M321.4M544.0M774.3M
Total Liabilities i2.2B1.7B2.2B2.1B1.8B
Equity
Common Stock i104.6M104.6M104.6M95.1M95.1M
Retained Earnings i16.9B14.0B11.7B9.8B8.8B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i18.1B15.3B12.9B11.0B10.0B
Key Metrics
Total Debt i29.7M97.4M315.5M624.9M892.8M
Working Capital i9.5B7.5B5.4B4.8B5.0B

Balance Sheet Composition

Concord Biotech Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i4.9B4.1B3.2B2.4B3.1B
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-1.9B-678.3M-886.6M-587.0M-670.8M
Operating Cash Flow i3.0B3.4B2.3B1.8B2.4B
Investing Activities
Capital Expenditures i-1.1B-855.1M-1.5B-1.6B-2.0B
Acquisitions i-----
Investment Purchases i-8.7B-8.4B-6.4B-5.2B-6.7B
Investment Sales i8.3B7.7B6.2B5.6B6.8B
Investing Cash Flow i-1.6B-1.6B-1.6B-1.2B-2.0B
Financing Activities
Share Repurchases i-----
Dividends Paid i-915.4M-714.5M-535.6M-705.2M-57.1M
Debt Issuance i--00519.7M
Debt Repayment i-58.6M-250.1M-250.0M-250.0M-187.5M
Financing Cash Flow i-972.4M-950.7M-796.7M-932.0M326.2M
Free Cash Flow i1.3B1.8B1.0B519.7M-373.6M
Net Change in Cash i382.8M907.1M-120.4M-325.5M819.0M

Cash Flow Trend

Concord Biotech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 46.08
Forward P/E 31.35
Price to Book 9.03
Price to Sales 13.78
PEG Ratio -1.76

Profitability Ratios

Profit Margin 29.97%
Operating Margin 21.38%
Return on Equity 20.50%
Return on Assets 18.27%

Financial Health

Current Ratio 6.17
Debt to Equity 0.16
Beta 0.95

Per Share Data

EPS (TTM) ₹33.97
Book Value per Share ₹173.28
Revenue per Share ₹113.54

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
concordbio163.9B46.089.0320.50%29.97%0.16
Biocon 456.0B105.911.883.66%2.44%66.26
OneSource Specialty 207.3B-1,098.043.48-0.31%-0.85%16.03
Blue Jet Healthcare 112.1B32.2010.1726.93%29.35%1.76
Supriya Lifescience 59.7B33.726.0018.86%26.16%0.54
Dishman Carbogen 44.9B42.360.760.06%3.60%40.97

Financial data is updated regularly. All figures are in the company's reporting currency.